Exhibit 5.2
![LOGO](https://capedge.com/proxy/8-K/0001193125-23-048910/g575646g0224053412464.jpg)
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285
U.S.A.
+1.317.276.2000
www.lilly.com
February 24, 2023
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285
Ladies and Gentlemen:
I am the Senior Director – Corporate Securities and Assistant Secretary of Eli Lilly and Company, an Indiana corporation (the “Company”). I am rendering this opinion in connection with the proposed issuance by the Company of $750,000,000 aggregate principal amount of the Company’s 5.000% Notes due 2026 (the “5.000% Notes”), $1,000,000,000 aggregate principal amount of the Company’s 4.700% Notes due 2033 (the “4.700% Notes”), $1,250,000,000 aggregate principal amount of the Company’s 4.875% Notes due 2053 (the “4.875% Notes”) and $1,000,000,000 aggregate principal amount of the Company’s 4.950% Notes due 2063 (the “4.950% Notes” and, collectively with the 5.000% Notes, the 4.700% Notes and the 4.875% Notes, the “Notes”) pursuant to a prospectus supplement dated February 23, 2023 to the prospectus dated February 24, 2022 contained in the Company’s Registration Statement on Form S-3 (File No. 333-262943) (the “Registration Statement”) filed with the U.S. Securities and Exchange Commission (the “Commission”) on February 24, 2022 under the Securities Act of 1933, as amended (the “Securities Act”), and pursuant to an Indenture, dated February 1, 1991, between the Company and Deutsche Bank Trust Company Americas (as successor to Citibank, N.A.), as trustee (the “Indenture”), and an Underwriting Agreement dated February 23, 2023 (the “Underwriting Agreement”), among the Company and J.P. Morgan Securities LLC, Credit Suisse Securities (USA) LLC, Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters named on Schedule 1 therein.
I have examined and am familiar with originals, or copies certified or otherwise identified to my satisfaction, of such documents, corporate records, certificates of officers of the Company and of public officials and such other instruments as I have deemed necessary or appropriate as a basis for the opinions expressed below, including the Registration Statement, the Company’s Amended Articles of Incorporation, the Company’s Bylaws, the Indenture, the global notes representing the Notes and the Underwriting Agreement.
For purposes of the opinions expressed below, I have assumed, without independent investigation, that (i) the Indenture and the Underwriting Agreement have been duly authorized, executed and delivered by the parties thereto other than the Company and constitute valid and binding obligations of the parties thereto other than the Company, enforceable against each of them in accordance with their respective terms; and